TY - JOUR AU - Huang, Ching-Hui AU - Chang, Chia-Chu PY - 2019 TI - Vitamin Cā€™s essential role in DNA and histone demethylation and a preclinical rationale for its therapeutic high-dose potential in renal cell carcinoma JF - Annals of Translational Medicine; Vol 7, Supplement 3 (July 30, 2019): Annals of Translational Medicine Y2 - 2019 KW - N2 - Renal cell carcinoma (RCC) accounts for 2ā€“3% of all malignancies in adults and 85% of all cases of adult kidney cancer (1). With an insidious disease course, nearly 25ā€“30% of patients will present with metastatic RCC (2). Otherwise, 30% of patients undergoing nephrectomy progress to distant metastasis or local recurrence during follow-up (3). It is important to be able to predict the risk of early RCC recurrence (4,5). The last two decades have witnessed the development of a number of targeted therapies including tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors, but these advancements have largely ignored first-line and subsequent therapies for patients with metastatic RCC (6). It is clear that there is a need for new therapy strategies in advanced RCC. UR - https://atm.amegroups.org/article/view/26175